Dexcom (DXCM) Shares Outstanding (Diluted Average) (2013 - 2026)

Dexcom (DXCM) has 14 years of Shares Outstanding (Diluted Average) data on file, last reported at $393.6 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $393.6 million, down 3.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $393.6 million (down 3.41% YoY), and the FY2025 annual result was $405.5 million, down 1.74% from the prior year.
• Shares Outstanding (Diluted Average) retreated to $393.6 million in Q1 2026 per DXCM's latest filing, from $405.5 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $431.5 million in Q2 2023 and troughed at $393.6 million in Q1 2026.
• A 5-year average of $416.8 million and a median of $416.8 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Diluted Average) jumped 309.85% in 2022, then dropped 4.23% in 2024.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $427.5 million in 2022, then slipped by 0.47% to $425.5 million in 2023, then dropped by 3.01% to $412.7 million in 2024, then retreated by 1.74% to $405.5 million in 2025, then retreated by 2.93% to $393.6 million in 2026.
• Business Quant data shows DXCM's Shares Outstanding (Diluted Average) at $393.6 million in Q1 2026, $405.5 million in Q4 2025, and $407.7 million in Q3 2025.